Lung cancer remains a major health challenge in Australia, with over 15,000 new diagnoses each year and low 5-year survival rates around 27%. [1] Delayed detection of incidental findings, inconsistent follow-up, and growing pressure on imaging and specialist services continue to contribute to later diagnosis. These pain points can lead to unnecessary anxiety for patients and missed opportunities for earlier intervention, highlighting the need for tools that support timely recognition and coordinated health systems.

This TGA clearance poises Optellum to help thousands of patients in Australia by supporting earlier and more consistent identification of incidental lung nodules. By helping care teams prioritize higher-risk findings and streamline follow-up more efficiently, VNC aims to reduce delays and uncertainty along the lung cancer care pathway. This clearance marks an important step in bringing validated AI tools into everyday clinical workflows, without replacing clinical judgment.